Natixis’s Soleno Therapeutics SLNO Stock Holding History

Natixis’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-692	Closed	-$23.2K	–	1351
2026 Q1	$23.2K	Sell	692 -13,148	-95%	-$515K	﹤0.01%	1005
2025 Q4	$641K	Buy	+13,840	New	+$759K	﹤0.01%	799

Natixis's SLNO Position: Q2 2026 in Review

Natixis sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 692 shares — an estimated $23.2K sold.

Natixis first reported a position in SLNO in Q4 2025 and held it in 2 quarters. The position peaked at $641K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Natixis reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Natixis sold 692 Soleno Therapeutics shares in Q2 2026, an estimated $23.2K.
Natixis first reported a position in Soleno Therapeutics in Q4 2025 and held it in 2 quarters.
Natixis's Soleno Therapeutics position peaked at $641K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.